135 related articles for article (PubMed ID: 38555235)
21. [Apalutamide, Erleada®].
Sautois B; Denis C
Rev Med Liege; 2022 Oct; 77(10):609-615. PubMed ID: 36226398
[TBL] [Abstract][Full Text] [Related]
22. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
Madan RA; Karzai F; Donahue RN; Al-Harthy M; Bilusic M; Rosner II; Singh H; Arlen PM; Theoret MR; Marté JL; Cordes L; Couvillon A; Hankin A; Williams M; Owens H; Lochrin SE; Chau CH; Steinberg S; Figg WD; Dahut W; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33664086
[TBL] [Abstract][Full Text] [Related]
24. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
[TBL] [Abstract][Full Text] [Related]
25. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
26. Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
Fukuoka K; Teishima J; Nagamatsu H; Inoue S; Hayashi T; Mita K; Shigeta M; Kobayashi K; Kajiwara M; Kadonishi Y; Tacho T; Matsubara A
Int Urol Nephrol; 2020 Jan; 52(1):77-85. PubMed ID: 31552574
[TBL] [Abstract][Full Text] [Related]
27. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Oudard S; Hadaschik B; Saad F; Cella D; Basch E; Graff JN; Uemura H; Dibaj S; Li S; Brookman-May SD; De Porre P; Bevans KB; Trudeau JJ; Small EJ; Smith MR
Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
[TBL] [Abstract][Full Text] [Related]
28. Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Int J Clin Oncol; 2019 Jul; 24(7):842-847. PubMed ID: 30739263
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
[TBL] [Abstract][Full Text] [Related]
30. Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate.
Janzen BW; Ong A; Penner M; Koul R; Dubey A; Ahmed S; Bashir B; Chowdhury A; Dawe DE; Nayak J; Kim JO
Am J Clin Oncol; 2020 Dec; 43(12):865-871. PubMed ID: 32976179
[TBL] [Abstract][Full Text] [Related]
31. Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.
Fujmoto S; Fujita K; Nishimoto M; Hamaguchi M; Kuwahara K; Hashimoto M; Adomi S; Minami T; Nozawa M; Yoshimura K; Uemura H
Cancer Med; 2023 Feb; 12(3):3176-3179. PubMed ID: 36043427
[TBL] [Abstract][Full Text] [Related]
32. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer.
Iwamoto H; Kano H; Shimada T; Naito R; Makino T; Kadamoto S; Yaegashi H; Shigehara K; Izumi K; Kadonoa Y; Mizokami A
In Vivo; 2021; 35(2):1247-1252. PubMed ID: 33622927
[TBL] [Abstract][Full Text] [Related]
34. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives.
Berruti A; Bracarda S; Caffo O; Cortesi E; D'Angelillo R; Del Re M; Facchini G; Pappagallo G; Procopio G; Sabbatini R; Santini D
Cancer Treat Rev; 2023 Apr; 115():102525. PubMed ID: 36822009
[TBL] [Abstract][Full Text] [Related]
35. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
Smith MR; Thomas S; Gormley M; Chowdhury S; Olmos D; Oudard S; Feng FY; Rajpurohit Y; Urtishak K; Ricci DS; Rooney B; Lopez-Gitlitz A; Yu M; Wyatt AW; Li M; Attard G; Small EJ
Clin Cancer Res; 2021 Aug; 27(16):4539-4548. PubMed ID: 34112710
[TBL] [Abstract][Full Text] [Related]
36. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
Appukkuttan S; Farej R; Miles L; Purser M; Wen L
J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
[No Abstract] [Full Text] [Related]
37. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
Cattrini C; Caffo O; De Giorgi U; Mennitto A; Gennari A; Olmos D; Castro E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406564
[TBL] [Abstract][Full Text] [Related]
38. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN; Fizazi K; Saad F; Shore ND; De Giorgi U; Penson DF; Ferreira U; Efstathiou E; Madziarska K; Kolinsky MP; Cubero DIG; Noerby B; Zohren F; Lin X; Modelska K; Sugg J; Steinberg J; Hussain M;
N Engl J Med; 2020 Jun; 382(23):2197-2206. PubMed ID: 32469184
[TBL] [Abstract][Full Text] [Related]
39. Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Schmidt A; Anton A; Shapiro J; Wong S; Azad A; Kwan E; Spain L; Muthusamy A; Torres J; Parente P; Parnis F; Goh J; Joshua AM; Pook D; Gibbs P; Tran B; Weickhardt A
Asia Pac J Clin Oncol; 2021 Feb; 17(1):36-42. PubMed ID: 32970925
[TBL] [Abstract][Full Text] [Related]
40. A Prospective Trial of
Wang B; Liu C; Wei Y; Meng J; Zhang Y; Gan H; Xu X; Wan F; Pan J; Ma X; Hu S; Freedland SJ; Song S; Ye D; Zhu Y
Clin Cancer Res; 2020 Sep; 26(17):4551-4558. PubMed ID: 32527944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
